Vaccine adjuvants: A priority for vaccine research
Vaccine adjuvants: A priority for vaccine research
复制标题
DOI：
10.1016/j.vaccine.2009.12.084
复制
发表时间：
2010-03-11
期刊：
影响因子：
5.5
通讯作者：
Shattock, Robin J.
中科院分区：
文献类型：
--
作者：
Harandi, Ali M.;Medaglini, Donata;Shattock, Robin J.
疫苗佐剂的研讨会于2009年7月在布鲁塞尔的欧洲委员会举行，目的是确定关键的科学重点，因为它们与针对威胁生命的疾病开发有效的疫苗有关，尤其是与贫困相关的疾病，包括艾滋病毒/艾滋病（包括艾滋病毒/艾滋病） ，疟疾和结核病以及被忽视的传染病。根据辅助研究和相关技术的新进步以及潜在的挑战和障碍，确定了六个优先级，以加速改善或新颖的疫苗佐剂以供人类使用。
The workshop on vaccine adjuvants was held in July of 2009 at the European Commission in Brussels, with the goal of identifying key scientific priorities as they pertain to the development of effective vaccines against life-threatening diseases especially those associated with poverty, including HIV/AIDS, malaria and tuberculosis as well as neglected infectious diseases. On the basis of new advances in adjuvant research and related technology as well as potential challenges and roadblocks, six priorities were identified to accelerate development of improved or novel vaccine adjuvants for human use.